The summaries are free for public
use. The Chronic Liver Disease
Foundation will continue to add and
archive summaries of articles deemed
relevant to CLDF by the Board of
Trustees and its Advisors.
Abstract Details
HCV's days are numbered: next-generation direct-acting antivirals and host-targeting agents
Calle Serrano B, Manns MP. Antivir Ther. 2012;17(6 Pt B):1133-46. doi: 10.3851/IMP2425. Epub 2012 Oct 5.
Source
Department of Gastroenterology, Hepatology and Endocrinology, Hannover Medical School, Hannover, Germany.
Abstract
Chronic hepatitis C affects approximately 170 million people worldwide and is one of the leading causes of liver-related morbidity and mortality. Until 2011, the only therapeutic option was combination therapy of pegylated interferon and ribavirin, with efficacy rates around 50% and plenty of side effects. In the past months, important steps have been made towards a more effective antiviral therapy. However, we are still far from both highly efficient and well-tolerable ideal therapy. The development of new drugs against HCV is a very dynamic field. This review summarizes the up-to-date knowledge of the most significant anti-HCV compounds in development.